Medicilon reached the collaboration on preclinical IND services with Welman & Mingyu New Drug
著者：Medicilon アップロード：2022-07-05 閲読回数：
On June 23, 2022, Shanghai Medicilon Inc. （Medicilon）， Welman Pharmaceutical （Welman） and Shenzhen Mingyu New Drug Research and Development Co., Ltd. （Mingyu） signed a strategic collaboration on preclinical IND application services.
According to the strategic collaboration agreement, Medicilon will assist Welman and Mingyu in advancing the R&D process of one anti-cancer drug with 4 targets, providing better preclinical solutions. At the same time, Welman and Mingyu will give priority to Medicilon as the outsourcing provider of preclinical IND application services, including but not limited to drug discovery, pharmaceutical research, preclinical research and other R&D services.
About Welman
Welman Pharmaceutical is a leading innovative high-tech pharmaceutical manufacturing enterprise in China. The company's core products are piperacillin sodium sulbactam sodium and cefotaxime sodium sulbactam sodium for injection. Piperacillin sodium sulbactam sodium for injection was launched in 2005, while cefotaxime sodium sulbactam sodium for injection was launched in 2009. Through extensive clinical use and market promotion in recent years, the market demand for the products has grown rapidly.
About Mingyu
Shenzhen Mingyu New Drug Research and Development Co., Ltd., a wholly-owned subsidiary of Welman Pharmaceutical, is committed to outsourcing the transformation of innovative new drugs and to attract more innovative talents.
About Medicilon
Since the founding of our company in 2004, Medicilon （Stock Code: 688202.SH） has grown into one of the professional?drug discovery contract research organizations （CRO）？in China. Over the years, Medicilon keeps improving their services in?biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of 2021, Medicilon has provided new drug R&D services to more than 1,460 clients around the world, and participated in the R&D of 221 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.
上の：AI empowers the research and of innovative drugs, Medicilon and Langrui have reached collaboration
下に：Lockdown But Not Stop, Medicilon Researchers Continue to Fight
